tiprankstipranks
Trending News
More News >
Check-Cap (CHEK)
NASDAQ:CHEK
Advertisement

Check-Cap (CHEK) AI Stock Analysis

Compare
978 Followers

Top Page

CHEK

Check-Cap

(NASDAQ:CHEK)

Select Model
Select Model
Select Model
Underperform 26 (OpenAI - 4o)
Rating:26Underperform
Price Target:
Check-Cap's overall score reflects its significant financial challenges, primarily due to a lack of revenue generation and persistent losses. While the technical analysis hints at possible recovery, the valuation is weak due to negative profitability indicators. The company's strong equity position is a positive aspect, but without revenue, it faces substantial risks.

Check-Cap (CHEK) vs. SPDR S&P 500 ETF (SPY)

Check-Cap Business Overview & Revenue Model

Company DescriptionCheck-Cap Ltd. is a medical technology company that focuses on the development of C-Scan, an ingestible capsule-based system designed to detect polyps before they may transform into colorectal cancer. The company operates within the healthcare and medical device sectors, aiming to provide a patient-friendly, preparation-free screening option for colorectal cancer, enhancing early detection and prevention efforts.
How the Company Makes MoneyCheck-Cap generates revenue primarily through the development and commercialization of its C-Scan technology. Revenue streams include the sale of C-Scan systems and capsules to healthcare providers and institutions. The company may also earn income through partnerships or licensing agreements with larger healthcare or medical device companies, which can provide additional funding and distribution channels. Furthermore, Check-Cap might engage in collaborative research and development agreements that contribute to its revenue, especially as it seeks regulatory approvals and market expansion.

Check-Cap Financial Statement Overview

Summary
Check-Cap's financial health is precarious, with no revenue streams to support its operations, leading to continuous losses. The company's strong equity position and lack of debt provide a cushion, but the absence of revenue generation and persistent negative cash flows highlight significant risks.
Income Statement
10
Very Negative
Check-Cap's income statement reveals a lack of revenue generation over the years, with persistent negative net income and EBIT, indicating ongoing challenges in achieving profitability. The absence of revenue growth and consistently high operating losses underscore significant financial instability.
Balance Sheet
25
Negative
The balance sheet shows a strong equity position with zero total debt as of the latest report, which provides financial stability. However, the company's inability to generate revenue casts doubt on the sustainability of its equity position over the long term.
Cash Flow
15
Very Negative
The cash flow statement indicates negative operating and free cash flows, reflecting the company's operational inefficiencies. While there is a significant cash position, this is not backed by revenue-generating activities, posing a risk to cash burn over time.
BreakdownTTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit-22.00K-212.00K-405.00K-205.00K-148.00K-115.00K
EBITDA-13.35M-17.65M-18.69M-16.98M-13.69M-13.95M
Net Income-12.56M-17.57M-19.25M-17.09M-13.76M-13.60M
Balance Sheet
Total Assets18.09M25.02M45.44M55.66M19.64M9.43M
Cash, Cash Equivalents and Short-Term Investments17.82M24.76M41.70M51.56M17.78M7.68M
Total Debt0.000.00964.00K1.15M389.00K433.00K
Total Liabilities913.00K1.33M4.13M4.97M3.26M3.19M
Stockholders Equity17.18M23.69M41.31M50.69M16.38M6.23M
Cash Flow
Free Cash Flow-3.55M-17.04M-19.19M-17.27M-13.49M-13.01M
Operating Cash Flow-7.14M-16.95M-18.71M-16.26M-13.11M-12.84M
Investing Cash Flow13.39M21.36M-12.51M-16.01M-10.45M5.45M
Financing Cash Flow0.000.008.85M51.02K23.58M6.51M

Check-Cap Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.26
Price Trends
50DMA
0.98
Positive
100DMA
0.90
Positive
200DMA
0.90
Positive
Market Momentum
MACD
0.44
Negative
RSI
69.85
Neutral
STOCH
47.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHEK, the sentiment is Positive. The current price of 2.26 is above the 20-day moving average (MA) of 1.42, above the 50-day MA of 0.98, and above the 200-day MA of 0.90, indicating a bullish trend. The MACD of 0.44 indicates Negative momentum. The RSI at 69.85 is Neutral, neither overbought nor oversold. The STOCH value of 47.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CHEK.

Check-Cap Risk Analysis

Check-Cap disclosed 70 risk factors in its most recent earnings report. Check-Cap reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Check-Cap Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
216.80M-4.91-256.51%22.56%41.62%
53
Neutral
10.06B-9.90-40.71%12.56%-464.28%
52
Neutral
718.30M-1.81-101.83%3.83%-137.31%
50
Neutral
1.02B-9.64-12.18%9.70%-30.94%
46
Neutral
382.90M-4.50-327.88%5.94%25.16%
26
Underperform
$12.58M-74.17%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CHEK
Check-Cap
2.26
0.91
67.41%
APDN
Applied DNA Sciences
2.91
-754.59
-99.62%
NDRA
ENDRA Life Sciences
4.90
-2.28
-31.75%
INBS
Intelligent Bio Solutions
1.28
-0.57
-30.81%
MYNZ
Mainz Biomed B.V.
1.55
-7.01
-81.89%
BIAF
bioAffinity Technologies, Inc.
3.41
-55.69
-94.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 30, 2025